{"type":"rich","author_name":"towermansion","title":"KRAS G12C+, Stage IV NSCLC\uff5eCodeBreak200 ","provider_url":"https://hatena.blog","width":"100%","height":"190","provider_name":"Hatena Blog","description":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial ARTICLES| VOLUME 401, ISSUE 10378, P733-746, MARCH 04, 2023 THE LANCET Summary <Background>Sotorasib is a specific, irreversible inhibitor of the GTPase protei\u2026","version":"1.0","url":"https://towermansion.hatenablog.com/entry/2024/02/23/233441","blog_url":"https://towermansion.hatenablog.com/","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Ftowermansion.hatenablog.com%2Fentry%2F2024%2F02%2F23%2F233441\" title=\"KRAS G12C+, Stage IV NSCLC\uff5eCodeBreak200  - \u52c9\u5f37\u7528\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","published":"2024-02-23 23:34:41","author_url":"https://blog.hatena.ne.jp/towermansion/","image_url":null,"categories":["lung cancer\uff5eNSCLC\uff5eStageIV\uff5eDriver+"],"blog_title":"\u52c9\u5f37\u7528"}